Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in BFLY.
← Back to Free Index

BFLY

Analysis as of: 2026-02-28
Butterfly Network, Inc.
Butterfly Network sells handheld ultrasound probes and a subscription cloud workflow that helps clinicians and health systems capture, manage, and share bedside imaging.
ai healthcare medical devices semiconductors software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

From handheld device to governed imaging workflow
Upside comes from converting probe installs into facility-level workflow fees and repeatable embedded licensing, not just selling more hardware. The main risks are dilution before profitability and incumbent bundling into enterprise imaging contracts.

Analysis

Thesis
Non-linear upside comes if handheld ultrasound shifts from “a cheap probe” to a governed enterprise workflow: facility-level contracts, compliance/provenance, and embedded licensing expand value capture even as AI commoditizes interpretation.
Last Economy Alignment
AI can expand bedside imaging volume by reducing skill friction, but value capture must move from seat pricing to workflow/trust control points to avoid being bundled by incumbents.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
3.5x (from 5 most recent analyses)
Reasoning
The 5-year underwriting hinges on BFLY turning its installed base into a repeatable enterprise rollout motion: more probes per health system, higher recurring attachment via workflow/documentation modules, and a growing contribution from embedded/co-development licensing that is less tied to hospital capital cycles. In a world where AI makes reading images cheaper, the durable budget shifts toward governance (who scanned, how it was captured, auditability), integration into clinical documentation, and fleet-level standardization—areas where BFLY can charge per facility or per pathway rather than per user. The multiple is constrained by competitive bundling risk and by the reality that credentialing/training throttles adoption speed.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The two binding risks are (1) financing/dilution before a durable self-funding model is reached, and (2) competitive bundling by large ultrasound vendors who already own hospital purchasing relationships and image-archive workflows. A slower-moving throttle is workforce training/credentialing: even with cheaper devices and AI guidance, institutions still need governance to expand scanning safely. Finally, embedded/co-development revenue can improve margins but increases partner concentration and quarter-to-quarter lumpiness.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.30
They control a regulated handheld imaging device plus an audited cloud workflow, so AI that makes image interpretation cheaper can actually increase scan volume and pull more data into their system. The threat is incumbents bundling similar tools and the slow training/credentialing machinery that limits how fast bedside imaging can scale.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$5.06
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case